Exelixis, Inc. — Biotechnology. Scored on the same transparent 7-signal model behind the daily rankings.
★
EXEL
Exelixis, Inc. · Biotechnology
FCF$918mC+
Rev+7.0%C+
D/E0.09B+
P/E18.8xA-
PEG2.56C
74.6Score
$56.78$14.3B
1Y Target$50.38Analyst consensus · 16 analysts
5Y Target$73.75Compound horizon
10Y Target$109.41Long-dated conviction
FCF$918mTTMC+
FCF $918m — respectable but not differentiating
Rev+7.0%TTM YoYC+
Revenue +7.0% — steady but below market-beating range
D/E0.09B+
D/E 0.09 — below the Healthcare debt median (≈40th pctile)
P/E18.8xA-
P/E 18.8 — cheaper than most Healthcare peers (≈25th pctile)
PEG2.56C
PEG 2.56 — expensive relative to growth rate
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 74.6
Quality0.96
Growth0.82
Value0.52
Why this score
Buying back stock
Durable high returns
Entry · Margin of safety
52-week rangeNear 52-week high
1% off the 12-month high
vs DCF fair value15% belowest. fair value ~$67
Quality signals · context only
Gross profitability88% · Agross profit ÷ total assets (Novy-Marx)
ROIC34.8% · Areturn on invested capital — not score-weighted
Why now
Biotechnology · market cap $14.3b. Trading near 52-week high of $57.57 — momentum setup, limited technical margin of safety. 16 sell-side analysts rate this a Buy with a mean 1-yr target of $50.38 (implying -11% upside).
Moat
Net margin 35% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 110% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $50.38 (16-analyst consensus) — fundamentals + valuation re-rating. 5 yr $73.75 at ~5% CAGR — compounding case rests on the competitive position widening. 10 yr $109.41 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Score history · EXEL
Trend
+1.2 over 14 daily scores
From 73.4 (Jun 22) → 74.6 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · EXEL
$
%
%
Shares to buy
35
Position size
$1,987
4.0% of portfolio
Stop price
$42.59
25% below $56.78
$ at risk if stopped
$496.87
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Exelixis, Inc. (EXEL): score, valuation & FAQ
Exelixis, Inc. (EXEL) is a Biotechnology company that scores 74.6 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/E (A-) and D/E (B+). On valuation, EXEL sits about 15% below our discounted-cash-flow fair value (a margin of safety).
Is EXEL a good stock to buy?
Bull Rankings scores EXEL 74.6 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by P/E (A-) and D/E (B+). A score is a quantitative screen of Exelixis, Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does EXEL score 74.6 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). EXEL earns its highest marks on P/E (A-) and D/E (B+). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is EXEL overvalued or undervalued?
Based on $56.78, EXEL sits about 15% below our discounted-cash-flow fair value (a margin of safety). It trades at a 18.8x× P/E (graded A-). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in EXEL?
Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.